ATE540044T1 - Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür - Google Patents

Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür

Info

Publication number: ATE540044T1
Authority: AT; Austria
Prior art keywords: treating; methods; lpa; antagonists; lpa receptor
Prior art date: 2003-10-09

Application number

AT04809934T

Other languages

English (en)

Inventor

Duane Miller

Gabor Tigyi

Gangadhar Durgam

Tamas Virag

Michelle Walker

Ryoko Tsukahara

Original Assignee

Univ Tennessee Res Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-09

Filing date

2004-10-12

Publication date

2012-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34421820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540044(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-10-12 Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE540044T1 publication Critical patent/ATE540044T1/de

Links

238000000034 method Methods 0.000 title abstract 3
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 3
108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 3
210000000056 organ Anatomy 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000004663 cell proliferation Effects 0.000 abstract 1
238000012258 culturing Methods 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1653—Esters of thiophosphoric acids with arylalkanols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/17—Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/173—Esters of thiophosphoric acids with unsaturated acyclic alcohols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT04809934T 2003-10-09 2004-10-12 Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür ATE540044T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50997103P	2003-10-09	2003-10-09
PCT/US2004/033601 WO2005032494A2 (en)	2003-10-09	2004-10-12	Lpa receptor agonists and antagonists and methods of use

Publications (1)

Publication Number	Publication Date
ATE540044T1 true ATE540044T1 (de)	2012-01-15

Family

ID=34421820

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04809934T ATE540044T1 (de)	2003-10-09	2004-10-12	Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür

Country Status (9)

Country	Link
US (3)	US7217704B2 (de)
EP (3)	EP2433946B1 (de)
JP (1)	JP5048333B2 (de)
KR (2)	KR101390040B1 (de)
AT (1)	ATE540044T1 (de)
AU (1)	AU2004278042B2 (de)
CA (1)	CA2540809C (de)
DK (1)	DK1678096T3 (de)
WO (1)	WO2005032494A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060270634A1 (en) *	2005-05-06	2006-11-30	Miller Duane D	Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
AU2006270066A1 (en)	2005-07-19	2007-01-25	University Of Tennessee Research Foundation	LPA2 receptor agonist inhibitors of CFTR
EP2099469A4 (de) *	2006-11-15	2013-02-27	Univ Tennessee Res Foundation	Strahlungsschutz und behandlung für gammastrahlenexposition
HUE040417T2 (hu)	2007-05-04	2019-03-28	Marina Biotech Inc	Aminosavlipidek és alkalmazásuk
EP2767541A1 (de) *	2008-03-03	2014-08-20	Rxbio, Inc.	LPA-Rezeptoragonisten und -antagonisten
WO2010016590A1 (ja)	2008-08-07	2010-02-11	国立大学法人長崎大学	全身性疼痛症候群の治療または予防薬
EP2346885B1 (de)	2008-11-05	2013-08-28	Clariant International Ltd.	Verfahren zur herstellung von monocarboxyfunktionaslisierten dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
WO2010051893A1 (de)	2008-11-07	2010-05-14	Clariant International Ltd	Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels acrylsäurederivaten und ihre verwendung
DE102008056341A1 (de)	2008-11-07	2010-05-12	Clariant International Limited	Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008060035A1 (de)	2008-12-02	2010-06-10	Clariant International Limited	Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de)	2008-12-04	2010-06-10	Clariant International Limited	Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063668A1 (de)	2008-12-18	2010-07-01	Clariant International Limited	Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063642A1 (de)	2008-12-18	2010-06-24	Clariant International Limited	Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
ES2446666T3 (es)	2008-12-18	2014-03-10	Clariant Finance (Bvi) Limited	Procedimiento para la preparación de ácidos etilen-dialquil-fosfínicos, o de sus ésteres y sales, mediante acetileno, y su utilización
DE102008063627A1 (de)	2008-12-18	2010-06-24	Clariant International Limited	Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de)	2008-12-19	2010-06-24	Clariant International Limited	Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
GB2470833B (en)	2009-06-03	2011-06-01	Amira Pharmaceuticals Inc	Polycyclic antagonists of lysophosphatidic acid receptors
GB2474748B (en)	2009-10-01	2011-10-12	Amira Pharmaceuticals Inc	Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) *	2010-06-14	2011-12-22	Amidra Pharmaceuticals, Inc.	Lysophosphatidic acid receptor antagonist and uses thereof
JP6039559B2 (ja)	2010-09-02	2016-12-07	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
US9034820B2 (en)	2011-03-14	2015-05-19	Hsinyu Lee	Method and composition for modulating erythropoiesis
WO2012138797A1 (en)	2011-04-05	2012-10-11	Amira Pharmaceuticals, Inc.	3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
JP2014525932A (ja)	2011-08-15	2014-10-02	インターミューン，インコーポレイテッド	リゾホスファチド酸レセプターアンタゴニスト
JP2015084649A (ja) *	2012-01-06	2015-05-07	国立大学法人東北大学	リゾリン脂質シグナル制御による幹細胞の維持増殖培養法
WO2015102856A1 (en) *	2013-12-30	2015-07-09	Rxbio Inc.	Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
US20170007559A1 (en) *	2015-07-12	2017-01-12	The University Of Tennessee Research Foundation	Compositions and methods for protecting colonic epithelial barrier function
PH12022550225A1 (en)	2019-07-30	2022-12-19	Taisho Pharmaceutical Co Ltd	Urea compound for antagonizing lpa1 receptor
JP2022115836A (ja) *	2021-01-28	2022-08-09	大正製薬株式会社	Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2735832A (en) *		1956-02-21		Bx s sx p px s sx e e
US5565439A (en) *	1992-11-24	1996-10-15	The Procter & Gamble Company	Methods of using lysophosphatidic acid for treating hyperproliferative conditions
US6495532B1 (en) *	1997-03-19	2002-12-17	Sky High, Llc	Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
DE69836972D1 (de) *	1997-03-19	2007-03-15	Sky High Llc	Lysophophasäure enthaltende zusammensetzungen die die apoptose hemmen und deren verwendung
EP1069895A4 (de) *	1998-03-18	2002-07-31	Lxr Biotechnology Inc	Zusammenstellungen die lysophosphatidylsäure enthalten welche apoptosis hemmen und deren verwendungen
US6852213B1 (en) *	1999-09-15	2005-02-08	Nalco Energy Services	Phosphorus-sulfur based antifoulants
CA2402038C (en) *	2000-03-17	2011-03-15	The University Of Tennessee Research Corporation	Lpa receptor agonists and antagonists and methods of use
US20030130237A1 (en) *	2000-03-17	2003-07-10	Miller Duane D.	LPA receptor agonists and antagonists and methods of use

2004
- 2004-10-12 AT AT04809934T patent/ATE540044T1/de active
- 2004-10-12 WO PCT/US2004/033601 patent/WO2005032494A2/en not_active Ceased
- 2004-10-12 EP EP11183960.1A patent/EP2433946B1/de not_active Expired - Lifetime
- 2004-10-12 JP JP2006534462A patent/JP5048333B2/ja not_active Expired - Fee Related
- 2004-10-12 EP EP11183958.5A patent/EP2481743B1/de not_active Expired - Lifetime
- 2004-10-12 AU AU2004278042A patent/AU2004278042B2/en not_active Ceased
- 2004-10-12 CA CA2540809A patent/CA2540809C/en not_active Expired - Fee Related
- 2004-10-12 US US10/963,085 patent/US7217704B2/en not_active Expired - Lifetime
- 2004-10-12 DK DK04809934.5T patent/DK1678096T3/da active
- 2004-10-12 KR KR1020127022661A patent/KR101390040B1/ko not_active Expired - Fee Related
- 2004-10-12 EP EP04809934A patent/EP1678096B1/de not_active Expired - Lifetime
2006
- 2006-05-09 KR KR1020067009011A patent/KR101216266B1/ko not_active Expired - Fee Related
2007
- 2007-05-14 US US11/748,331 patent/US7947665B2/en not_active Expired - Lifetime
2011
- 2011-05-23 US US13/114,010 patent/US20120135967A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2540809A1 (en)	2005-04-14
DK1678096T3 (da)	2012-04-23
CA2540809C (en)	2013-09-24
EP2433946B1 (de)	2016-04-20
JP5048333B2 (ja)	2012-10-17
KR101216266B1 (ko)	2012-12-28
WO2005032494A3 (en)	2005-09-15
JP2007508324A (ja)	2007-04-05
US7947665B2 (en)	2011-05-24
AU2004278042A1 (en)	2005-04-14
WO2005032494A2 (en)	2005-04-14
EP2433946A1 (de)	2012-03-28
EP1678096A2 (de)	2006-07-12
US20120135967A1 (en)	2012-05-31
US20060009507A1 (en)	2006-01-12
EP1678096A4 (de)	2007-04-18
KR20060118469A (ko)	2006-11-23
US7217704B2 (en)	2007-05-15
KR101390040B1 (ko)	2014-04-29
KR20120120385A (ko)	2012-11-01
EP2481743B1 (de)	2017-03-22
EP1678096B1 (de)	2012-01-04
EP2481743A1 (de)	2012-08-01
US20080090783A1 (en)	2008-04-17
AU2004278042B2 (en)	2012-02-09

Publication	Publication Date	Title
ATE540044T1 (de)	2012-01-15	Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür
DK1263752T3 (da)	2008-04-14	LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
BR0306988A (pt)	2004-11-23	Piridazinonas substituìdas como inibidores de p38
CY1118768T1 (el)	2017-07-12	Ετεροκυκλικοι ρυθμιστες μεταφορεων κασετας συνδεσης atp
PA8550101A1 (es)	2003-09-05	Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
NO20075992L (no)	2008-02-13	Forbindelser som modulerer C-Kit og C-FMS aktivitet og anvendelser derav
LTPA2016016I1 (lt)	2016-06-10	Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
BR0313330A (pt)	2005-06-14	Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
EA200401284A1 (ru)	2005-04-28	Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
EA200801291A1 (ru)	2008-12-30	Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
CY1115489T1 (el)	2017-01-04	ΠΑΡΑΛΛΑΓΜΑΤΑ ΠΡΟΕΡΧΟΜΕΝΑ ΑΠΟ ActRIIB ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UY29458A1 (es)	2006-11-30	Heterociclos sustituidos y usos de los mismos
BRPI0418251B8 (pt)	2019-10-08	fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
TW200638934A (en)	2006-11-16	Heteroaryl compounds as P2Y1 receptor inhibitors
UA83311C2 (en)	2008-06-25	3-aminocyclopentanecarboxamides as modulators of chemokine receptors
ATE288747T1 (de)	2005-02-15	Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
TW200608966A (en)	2006-03-16	3-aminocyclopentanecarboxamides as modulators of chemokine receptors
UA83917C2 (en)	2008-08-26	3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
UA84954C2 (ru)	2008-12-10	Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
ATE383345T1 (de)	2008-01-15	Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
WO2003024402A3 (en)	2004-02-19	Lpa receptor agonists and antagonists and methods of use
BR0307903A (pt)	2006-04-04	derivados de arilsulfona
DE60316128D1 (de)	2007-10-18	N-sulfonylurea-apoptosis-förderer
BRPI0416994A (pt)	2007-02-06	inibidores de proteìna cinase com base em indolinona avançada
JO2747B1 (en)	2014-03-15	Vehicles